ASPIRE BIOPHARMA HOLDINGS IN (ASBP) Fundamental Analysis & Valuation

NASDAQ:ASBP • US7389202067

Current stock price

0.7181 USD
+0.06 (+9.22%)
At close:
0.7001 USD
-0.02 (-2.51%)
After Hours:

This ASBP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ASBP Profitability Analysis

1.1 Basic Checks

  • ASBP had negative earnings in the past year.
  • ASBP had a negative operating cash flow in the past year.
ASBP Yearly Net Income VS EBIT VS OCF VS FCFASBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2022 2023 2024 0 -5M -10M

1.2 Ratios

  • The Return On Assets of ASBP (-1194.47%) is worse than 94.27% of its industry peers.
Industry RankSector Rank
ROA -1194.47%
ROE N/A
ROIC N/A
ROA(3y)-54.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASBP Yearly ROA, ROE, ROICASBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2022 2023 2024 0 100 -100

1.3 Margins

  • ASBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASBP Yearly Profit, Operating, Gross MarginsASBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ASBP Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ASBP has been reduced compared to 1 year ago.
  • The debt/assets ratio for ASBP is higher compared to a year ago.
ASBP Yearly Shares OutstandingASBP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M
ASBP Yearly Total Debt VS Total AssetsASBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -41.97, we must say that ASBP is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -41.97, ASBP is doing worse than 90.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -41.97
ROIC/WACCN/A
WACCN/A
ASBP Yearly LT Debt VS Equity VS FCFASBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • ASBP has a Current Ratio of 0.17. This is a bad value and indicates that ASBP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.17, ASBP is not doing good in the industry: 93.75% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.17 indicates that ASBP may have some problems paying its short term obligations.
  • The Quick ratio of ASBP (0.17) is worse than 93.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.17
ASBP Yearly Current Assets VS Current LiabilitesASBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ASBP Growth Analysis

3.1 Past

  • ASBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -282.27%.
EPS 1Y (TTM)-282.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. ASBP Valuation Analysis

4.1 Price/Earnings Ratio

  • ASBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASBP Price Earnings VS Forward Price EarningsASBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASBP Per share dataASBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASBP Dividend Analysis

5.1 Amount

  • ASBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASBP Fundamentals: All Metrics, Ratios and Statistics

ASPIRE BIOPHARMA HOLDINGS IN

NASDAQ:ASBP (3/20/2026, 8:00:01 PM)

After market: 0.7001 -0.02 (-2.51%)

0.7181

+0.06 (+9.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners8.75%
Inst Owner Change113.54%
Ins Owners7.47%
Ins Owner Change0%
Market Cap3.60M
Revenue(TTM)1.90K
Net Income(TTM)-28.70M
AnalystsN/A
Price TargetN/A
Short Float %8.63%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1897.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-65.94
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS-2.28
TBVpS-2.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1194.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.17
Altman-Z -41.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-282.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-317.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-496.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-496.37%
OCF growth 3YN/A
OCF growth 5YN/A

ASPIRE BIOPHARMA HOLDINGS IN / ASBP Fundamental Analysis FAQ

What is the fundamental rating for ASBP stock?

ChartMill assigns a fundamental rating of 0 / 10 to ASBP.


What is the valuation status for ASBP stock?

ChartMill assigns a valuation rating of 0 / 10 to ASPIRE BIOPHARMA HOLDINGS IN (ASBP). This can be considered as Overvalued.


What is the profitability of ASBP stock?

ASPIRE BIOPHARMA HOLDINGS IN (ASBP) has a profitability rating of 0 / 10.


How financially healthy is ASPIRE BIOPHARMA HOLDINGS IN?

The financial health rating of ASPIRE BIOPHARMA HOLDINGS IN (ASBP) is 0 / 10.